38results about "Androstane derivatives" patented technology

6-Methyloxaalkyl exemestane compounds and related compositions, as can be used, chemotherapeutically, to inhibit growth and proliferation of cancer cells.

The invention relates to a method of altering hypothalamic function in an individual. The method comprises nasally administering a human semiochemical, e.g. an Estrene steroid, or a pharmaceutical composition containing an Estrene steroid, such that the ligand semiochemical binds to a specific neuroepithelial receptor. The steroid is preferably administered in the form of a pharmaceutical composition containing one or more pharmaceutically acceptable carriers. Other embodiments of the invention include pharmaceutical compositions containing the steroids.

6-Methyloxaalkyl exemestane compounds and related compositions, as can be used, chemotherapeutically, to inhibit growth and proliferation of cancer cells.

Disclosed is the use of 5α-androstane(alkyl)-3β,5,6β-triol in preparing neuroprotective drugs. The compound has significant protective effect against neuron injuries caused by cerebral ischemia, spinal cord ischemia or hypoxia and has no obvious toxic reaction within effective dose thereof.

The present invention relates to novel steroidal compounds of formula (I), process for preparation of the same and composition comprising these compounds.

The present invention relates to SHIP inhibitor compounds and methods for using these compounds. In particular, the present invention discloses the following methods: (i) a method of treating graft versus host disease in a subject; (ii) a method of inhibiting a SHIP1 protein in a cell; (iii) a method of selectively inhibiting a SHIP1 protein in a cell; (iv) a method for treating or preventing graft-versus-host disease (GVHD) in a recipient of an organ or tissue transplant; (v) a method of modulating SHIP activity in a cell expressing SHIP1 or SHIP2; (vi) a method of ex vivo or in vitro treatment of transplants; (vii) a method of inhibiting tumor growth and metastasis in a subject; (viii) a method of treating a hematologic malignancy in a subject; (ix) a method of inducing apoptosis of multiple myeloma cells; (x) a method of treating multiple myeloma in a subject; (xi) a method of inhibiting the proliferation of a human breast cancer cell; and (xii) a method of treating breast cancer in a subject.

The present invention relates to four crystalline forms (crystalline forms A, B, C and D) of 5α-androstane-3β,5,6β-triol (YC-6) and preparation methods therefor. The four crystalline forms have significant difference in their lattice parameters, 2θ values and intensity in X-ray power diffraction, and melting points, etc. The study on its polymorphism is very important for further studying its effect, bioavailability and stability.

The invention discloses a reducing dehalogenating method of an organic halogenated compound. The reducing dehalogenating method comprises: mixing an organic halogenated compound R-X, a non-noble metalpromoter, a sulfide and an alkali, and carrying out a reducing dehalogenating reaction to obtain a reducing product R-H, wherein R is at least one selected from alkyl and aryl, and X is at least oneselected from iodine, bromine and chlorine. According to the present invention, the types and the ratio (especially the specific type of the promoter) of various raw materials used in the reducing dehalogenating reaction, the corresponding reaction conditions and the like are researched and improved, such that the problems of use of highly-toxic or expensive reagent, poor tolerance of the group, narrow application range of the substrate and the like in the prior art can be effectively solved.

Steroid compounds having various oxygen substitution on the steroid nucleus are disclosed. A specific functionality present on many of the steroid compounds is oxygen substitution at both of positions 6 and 7. Thus, certain steroids have oxygen substitution at C6 and C7, and some have specific stereochemistries such as 6α and 7β oxygen substitution, and an alpha hydrogen at the 5 position in addition to having 6α and 7β oxygen substitution. Steroids having 3,4-epoxy functionality are also disclosed. In addition, steroids having C17 pyran and δ-lactone functionality, with oxygen substitution at C6 and C7, or at C15, of the steroid nucleus, are disclosed.

The present invention relates to novel steroidal compounds of formula (I), process for preparation of the same and composition comprising these compounds.

The invention discloses a 17-Iodoandrosta-5,16-dien-3beta-ol preparation method. The 17-Iodoandrosta-5,16-dien-3beta-ol preparation method takes dehydroeopiandrosterone-17-hydrazone, trichloroisocyanuric acid (TCCA), tetramethyl guanidine (TMG) and elemental iodine as raw materials to react at 0-90 DEG C with existence of solvent and then performing treatment to obtain the 17-Iodoandrosta-5,16-dien-3beta-ol. According to the 17-Iodoandrosta-5,16-dien-3beta-ol preparation method, the TCCA serves as oxidizing agent, the elemental iodine serves as iodinating agent, an oxidizing iodination methodis applied to iodinating dehydroeopiandrosterone-17-hydrazone, so that, compared with traditional methods, the 17-Iodoandrosta-5,16-dien-3beta-ol preparation method can reduce consumption of the elemental iodine by a half and is simple in operation of reaction processes and easy to control, thereby having a good industrialized application prospect.

The invention discloses 12beta-hydroxy-androstane4,14-diene-16-ketone compounds or pharmaceutically acceptable salt thereof, and the application of the compounds to preparation of immunosuppressive medicines and anti-tumor medicines. The compounds are extracted and separated from epigynum plants, and the structural formula is as shown in the specification, wherein R is selected from hydrogen, methoxyl, ethyoxyl, halogen, aliphatic group and fat amino; and in the formula, the formula as shown in the description represents single bond or double bonds. The experiment proves that the compounds reported in the invention have high immunosuppressive activity and anti-tumor activity; and the compounds provided by the invention provide leading compounds for developing immunosuppressive preparationsand anti-tumor preparations, and are favorable for developing and utilizing plant medicinal resources.

The invention discloses a 17-Iodoandrosta-5,16-dien-3beta-ol preparation method. The 17-Iodoandrosta-5,16-dien-3beta-ol preparation method takes dehydroeopiandrosterone-17-hydrazone, trichloroisocyanuric acid (TCCA), tetramethyl guanidine (TMG) and elemental iodine as raw materials to react at 0-90 DEG C with existence of solvent and then performing treatment to obtain the 17-Iodoandrosta-5,16-dien-3beta-ol. According to the 17-Iodoandrosta-5,16-dien-3beta-ol preparation method, the TCCA serves as oxidizing agent, the elemental iodine serves as iodinating agent, an oxidizing iodination methodis applied to iodinating dehydroeopiandrosterone-17-hydrazone, so that, compared with traditional methods, the 17-Iodoandrosta-5,16-dien-3beta-ol preparation method can reduce consumption of the elemental iodine by a half and is simple in operation of reaction processes and easy to control, thereby having a good industrialized application prospect.

The invention discloses a reducing dehalogenating method of an organic halogenated compound. The reducing dehalogenating method comprises: mixing an organic halogenated compound R-X, a non-noble metalpromoter, a sulfide and an alkali, and carrying out a reducing dehalogenating reaction to obtain a reducing product R-H, wherein R is at least one selected from alkyl and aryl, and X is at least oneselected from iodine, bromine and chlorine. According to the present invention, the types and the ratio (especially the specific type of the promoter) of various raw materials used in the reducing dehalogenating reaction, the corresponding reaction conditions and the like are researched and improved, such that the problems of use of highly-toxic or expensive reagent, poor tolerance of the group, narrow application range of the substrate and the like in the prior art can be effectively solved.

The invention relates to the field of natural medicines, and discloses a steroidal compound which is derived from artocarpus heterophyllus pulp and has a novel chemical structure, a preparation method of the steroidal compound and application of the steroidal compound in antitumor medicines. Various in-vitro antitumor activity evaluation results of the compound artoheterophoid show that the compound has remarkable antitumor activity, presents protein tyrosine kinase inhibition activity equivalent to the tyrosine kinase inhibition activity of a positive control drug, can be further developed into an anti-tumor drug taking protein tyrosine kinase as a target, can be applied to the anti-tumor drug, is simple in separation and purification process and mild in reaction conditions, and has practical significance.

The present invention discloses compound 2β,3α,5α-trihydroxy-androst-6-one, having the structure of formula (I). The present invention also discloses a plurality of methods for preparing the compound and a use of the compound.

The present disclosure provides methods of preparing cholic acid, deoxycholic acid, or chenodeoxycholic acid, an ester thereof, or a pharmaceutically or cosmetically acceptable salt thereof, and novel and useful synthetic intermediates, for example, as described for methods 1, 1A, 1B, 2, 3, 3A, and 4. The method can start with a plant derived steroid as a starting material, such as dehydroepiandrosterone (DHEA) or Acetyl-dehydroepiandrosterone (Ac-DHEA). Also provided are pharmaceutical or cosmetic compositions and uses thereof, which comprise one or more of cholic acid, deoxycholic acid, or chenodeoxycholic acid, an ester thereof, or a pharmaceutically or cosmetically acceptable salt thereof, which is of high purity, for example, free of animal derived impurities.